Our study found that in patients with GC without BRCA1 mutations, the PARP1 inhibitor OLP combined with AIL inhibiting BRCA1, and they work hand in hand to inhibit HR and BER pathways with powerful anti‐tumour effects. Here, PARP1 is linked to neoplasm.